Job Code 227DR
Fate Therapeutics is currently seeking a talented and highly motivated genomic scientist with a strong background in Next Generation Sequencing (NGS) and single cell analysis methods to join a multidisciplinary team dedicated to the discovery of novel cellular therapeutics. The candidate will play a key role in NGS method development to perform genomic and transcriptomic characterization on Fate’s engineered iPSC derived NK and T cell cancer immunotherapy products. The successful candidate must have knowledge of cutting-edge genomic engineering techniques as well as a strong expertise in genomic and transcriptomic characterization of genetically modified cells, preferably in a single-cell environment. The position will require innovative thinking, strong independent and collaborative research abilities, and excellent oral and written communication skills. This is a full-time, bench-level position reporting to the Associate Director, Genomics and is located at the Company’s corporate headquarters in San Diego, California.
Download a PDF of the job description for more details:
For consideration send cover letter and curriculum vitae to: email@example.com and reference job 227DR.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.